CD7 CAR-T Cell Therapy Tested in Adults With Systemic Sclerosis
Tests CD7 CAR-T cells in adults with relapsed or hard-to-treat systemic sclerosis.
Plain-language title generated from the registry record
Registry title: Clinical Study of CD7 CAR-T Cells for Relapsed/refractory Autoimmune Diseases
Key facts
- Where
- Hefei, ChinaSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 70 years old?
Source: NCT06871644, who can take part
Where in China
- PersonGen Anke Cellular Therapeutice Co,Ltd.Hefei, ChinaNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- PersonGen BioTherapeutics (Suzhou) Co., Ltd.
- Trial code
- NCT06871644
- Record updated
- 12 March 2025
- Original description
The primary objective was to evaluate the safety of CD7 CAR-T cells for the treatment of subjects with relapsed/refractory AID. CD7 CAR-T cells were infused in a single infusion in subjects who were screened after signing an informed consent form and undergoing single nucleus cell collection and pretreatment, and blood was collected before and after the infusion for pharmacokinetic, pharmacodynamic, immunogenicity, and safety evaluations.Read full original descriptionShow less
CD7CAR-T Cell Therapy As a Single-Arm, Open-Label, Single-Center Investigator-Initiated Early-Stage Clinical Study
The primary objective was to evaluate the safety of CD7 CAR-T cells for the treatment of subjects with relapsed/refractory AID. CD7 CAR-T cells were infused in a single infusion in subjects who were screened after signing an informed consent form and undergoing single nucleus cell collection and pretreatment, and blood was collected before and after the infusion for pharmacokinetic, pharmacodynamic, immunogenicity, and safety evaluations.
Inclusion: Diagnosed relapsing/refractory systemic sclerosis that has failed treatment with at least two immunosuppressive and/or biologic agents; Bone marrow and coagulation function, liver and kidney function, cardiopulmonary function are satisfied No serious mental disorders.
Exclusion: Malignancy other than AID disease within 5 years prior to screening Hepatitis B surface antigen (HBsAg) positive, AIDS, syphilis and other virus positive persons Severe heart disease.